Action of FR901228, a Novel Antitumor Bicyclic Depsipeptide Produced by Chromo-bacterium violaceum No. 968, on Ha-ras Transformed NIH3T3 Cells
The DOI matches its Crossref record.
Abstract
FR901228, a novel antitumor antibiotic, reversed the transformed morphology of the Ha-ras transformants, Ras-1 cells, and inhibited their growth. The reduction of c-myc expression was observed in FR901228-treated Ras-1 cells by RNA dot-blot hybridization. This reduction of c-myc expression and morphological reversion of the transformed cells to normal were correlated with growth inhibition (G0/G1 arrest in cell cycle).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687
(2002) · PubMed · Cited by 732
UEDA, H., NAKAJIMA, H., HORI, Y., FUJITA, T., NISHIMURA, M., GOTO, T., & OKUHARA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.301 · Cited by 489
Self-citationFR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor
Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., & Horinouchi, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4027 · Cited by 487
Self-citationPiekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R., & Bates, S. E. (2001) · Blood · doi:10.1182/blood.v98.9.2865 · Cited by 445
An Overview of Drug Discovery and Development
Berdigaliyev, N., & Aljofan, M. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0307 · Cited by 396
Chemogenomics: an emerging strategy for rapid target and drug discovery
Bredel, M., & Jacoby, E. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1317 · Cited by 356
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Grant, C., Rahman, F., Piekarz, R., Peer, C., Frye, R., Robey, R. W., Gardner, E. R., Figg, W. D., & Bates, S. E. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.88 · Cited by 291
Sandor, V, Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M. V., & Bates, S. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1327 · Cited by 290
(2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832124100 · Cited by 283
Chromobacterium violaceum: A Review of Pharmacological and Industiral Perspectives
Durán, N., & Menck, C. F. M. (2001) · Critical Reviews in Microbiology · doi:10.1080/20014091096747 · Cited by 273
Marine organisms as a source of new anticancer agents
Schwartsmann, G., da Rocha, A. B., Berlinck, R. G., & Jimeno, J. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00292-8 · Cited by 261
UEDA, H., MANDA, T., MATSUMOTO, S., MUKUMOTO, S., NISHIGAKI, F., KAWAMURA, I., & SHIMOMURA, K. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.315 · Cited by 257
Self-citationDeath the Fas way: regulation and pathophysiology of CD95 and its ligand
Sharma, K., Wang, R. X., Zhang, L. Y., Yin, D. L., Luo, X. Y., Solomon, J. C., Jiang, R. F., Markos, K., Davidson, W., Scott, D. W., et al. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00096-6 · Cited by 199
Marine organisms and other novel natural sources of new cancer drugs
Schwartsmann, G. (2000) · Annals of Oncology · doi:10.1093/annonc/11.suppl_3.235 · Cited by 81
New molecular targeted therapies in thyroid cancer
Milano, A., Chiofalo, M. G., Basile, M., Salzano de Luna, A., Pezzullo, L., & Caponigro, F. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000224449.16329.c5 · Cited by 26
Metadata
- Authors
- Ueda, H., Nakajima, H., Hori, Y., Goto, T., & Okuhara, M.
- Venue
- Bioscience, Biotechnology, and Biochemistry
- Publisher
- Informa UK Limited
- Published
- 1994-01
- Volume
- 58
- Issue
- 9
- Pages
- 1579-1583
- ISSN
- 0916-8451 (ISSN-L)
- 1347-6947
- OpenAlex
- W1989184574
- Cited by
- 143
- References
- 0
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.